STOCK TITAN

Bausch Health Companies (BHC) Stock News, Nov 2021-Jan 2022

BHC NYSE

Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.

Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.

Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that CEO Joseph C. Papa will speak at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. A live webcast of the event will be available on the company's Investor Relations page. Bausch Health is committed to improving lives through a range of healthcare products, focusing on eye health, gastroenterology, and dermatology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the publication of a post-hoc analysis in The Journal of Emergency Medicine supporting RELISTOR (methylnaltrexone bromide) injection for treating opioid-induced constipation in severely ill patients with insufficient laxative response. The study revealed a significant increase in rescue-free laxation rates: 61.4% within 4 hours compared to 16% for placebo. Notably, RELISTOR did not compromise opioid pain relief, although gastrointestinal side effects were reported. This reinforces RELISTOR's therapeutic value, particularly in emergency settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
none
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its dermatology product, JUBLIA® (efinaconazole) Topical Solution, has received the American Podiatric Medical Association (APMA) Seal of Approval. This recognition signifies the product's safety and efficacy in treating onychomycosis, a common fungal infection affecting toenails. JUBLIA® has been available since 2014 for adults and was approved for children in 2020. The APMA's endorsement comes after a rigorous scientific review process, enhancing JUBLIA's credibility in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
none
-
Rhea-AI Summary

Bausch Health and Salix Pharmaceuticals launched digital initiatives for Constipation Awareness Month, focusing on opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C), and chronic idiopathic constipation (CIC). Their campaign aims to enhance patient education and awareness through platforms like TikTok and revamped websites, including UnderstandingOIC.com. Highlights include partnerships with healthcare influencers to discuss symptoms and treatment options, addressing the fact that 40-80% of chronic pain patients experience OIC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
-
Rhea-AI Summary

Bausch + Lomb, part of Bausch Health (NYSE/TSX: BHC), announced that its exclusive recycling programs, ONE by ONE and Biotrue®, have successfully recycled over 41 million units (248,516 pounds) of used contact lens and eye care materials. The Biotrue® program is the first of its kind in the U.S., having collected more than 65,000 units since launch. These initiatives, in partnership with TerraCycle, promote sustainability by addressing waste that typically ends up in landfills. The company aims to expand these efforts to further reduce environmental impact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
Rhea-AI Summary

Kroll Bond Rating Agency (KBRA) has released its Third-Quarter 2021 U.S. Bank Compendium, providing insights into the U.S. banking sector's performance and outlook for 2022. The report reviews 3Q21 results for U.S. banks under KBRA ratings, focusing on key credit metrics and ratios. Additionally, it highlights the top 10 banks with the lowest cost deposits and analyzes changes in return on assets and nonperforming asset ratios. The compendium also includes a detailed supplement of 187 rated bank debt issues. Amalgamated Financial Corp. (NASDAQ: AMAL) holds a BBB rating with a Stable Outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its gastroenterology business, Salix Pharmaceuticals, will present new data on rifaximin at The Liver Meeting™ 2021, taking place virtually from Nov. 12-15, 2021. Two abstracts will be available to registered attendees, highlighting studies on rifaximin's role in reducing hospitalization and mortality in patients with hepatic encephalopathy, as well as its use in emergency department services for cirrhosis patients. XIFAXAN® (rifaximin) is indicated for reducing hepatic encephalopathy recurrence and treating IBS-D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies (NYSE/TSX: BHC) announced its participation in two significant investor conferences. The leadership team, including Joseph C. Papa and Sam Eldessouky, will present at the Credit Suisse 30th Annual Healthcare Conference on Nov. 10, 2021, at 10:30 a.m. ET, and at the Evercore ISI HealthCONx Conference on Dec. 1, 2021, at 1:00 p.m. ET. A live webcast will be available on the company’s Investor Relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
Rhea-AI Summary

Bausch Health Companies reported third-quarter 2021 revenues of $2.111 billion, down 1% from $2.138 billion year-over-year. GAAP net income surged to $188 million, compared to $71 million in Q3 2020. The company plans to launch IPOs for Solta Medical in December 2021 or January 2022, followed by Bausch + Lomb about 30 days later. Bausch Health reaffirmed its full-year 2021 guidance with revenue expectations of $8.40 – $8.60 billion and Adjusted EBITDA between $3.35 – $3.50 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

Bausch Health Companies (BHC) last closed at $8.22.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately $3.1B.